NCT02587689, a Phase I/II trial, investigated the use of anti-MUC1 chimeric antigen receptor T-Cell Immunotherapy (CAR-T) cells for the treatment of MUC1-positive advanced solid tumors, including NSCLC, enrolling 20 patients. The gene discussed is MUC1; the disease is non-small cell lung carcinoma.